Akt as a therapeutic target in cancer.
Identifieur interne : 001654 ( Main/Exploration ); précédent : 001653; suivant : 001655Akt as a therapeutic target in cancer.
Auteurs : Linda S. Steelman [États-Unis] ; Kristin M. Stadelman ; William H. Chappell ; Stefan Horn ; Jörg B Secke ; Melchiorre Cervello ; Ferdinando Nicoletti ; Massimo Libra ; Franca Stivala ; Alberto M. Martelli ; James A. MccubreySource :
- Expert opinion on therapeutic targets [ 1744-7631 ] ; 2008.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Protéines proto-oncogènes c-akt.
- pharmacologie : Antinéoplasiques.
- traitement médicamenteux : Tumeurs.
- Animaux, Humains, Souris.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Proto-Oncogene Proteins c-akt.
- chemical , pharmacology : Antineoplastic Agents.
- drug therapy : Neoplasms.
- Animals, Humans, Mice.
Abstract
BACKGROUND
The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of growth regulatory signals originating from cell surface receptors.
OBJECTIVE
This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells.
METHODS
We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular.
RESULTS/CONCLUSIONS
The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.
DOI: 10.1517/14728222.12.9.1139
PubMed: 18694380
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Akt as a therapeutic target in cancer.</title><author><name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name><affiliation wicri:level="2"><nlm:affiliation>Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, Greenville, NC 27858, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, Greenville, NC 27858</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Stadelman, Kristin M" sort="Stadelman, Kristin M" uniqKey="Stadelman K" first="Kristin M" last="Stadelman">Kristin M. Stadelman</name></author><author><name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name></author><author><name sortKey="Horn, Stefan" sort="Horn, Stefan" uniqKey="Horn S" first="Stefan" last="Horn">Stefan Horn</name></author><author><name sortKey="B Secke, Jorg" sort="B Secke, Jorg" uniqKey="B Secke J" first="Jörg" last="B Secke">Jörg B Secke</name></author><author><name sortKey="Cervello, Melchiorre" sort="Cervello, Melchiorre" uniqKey="Cervello M" first="Melchiorre" last="Cervello">Melchiorre Cervello</name></author><author><name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name></author><author><name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name></author><author><name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18694380</idno><idno type="pmid">18694380</idno><idno type="doi">10.1517/14728222.12.9.1139</idno><idno type="wicri:Area/Main/Corpus">001586</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001586</idno><idno type="wicri:Area/Main/Curation">001586</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001586</idno><idno type="wicri:Area/Main/Exploration">001586</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Akt as a therapeutic target in cancer.</title><author><name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name><affiliation wicri:level="2"><nlm:affiliation>Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, Greenville, NC 27858, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, Greenville, NC 27858</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Stadelman, Kristin M" sort="Stadelman, Kristin M" uniqKey="Stadelman K" first="Kristin M" last="Stadelman">Kristin M. Stadelman</name></author><author><name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name></author><author><name sortKey="Horn, Stefan" sort="Horn, Stefan" uniqKey="Horn S" first="Stefan" last="Horn">Stefan Horn</name></author><author><name sortKey="B Secke, Jorg" sort="B Secke, Jorg" uniqKey="B Secke J" first="Jörg" last="B Secke">Jörg B Secke</name></author><author><name sortKey="Cervello, Melchiorre" sort="Cervello, Melchiorre" uniqKey="Cervello M" first="Melchiorre" last="Cervello">Melchiorre Cervello</name></author><author><name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name></author><author><name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name></author><author><name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name></author></analytic><series><title level="j">Expert opinion on therapeutic targets</title><idno type="eISSN">1744-7631</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antineoplastic Agents (pharmacology)</term><term>Humans (MeSH)</term><term>Mice (MeSH)</term><term>Neoplasms (drug therapy)</term><term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antinéoplasiques (pharmacologie)</term><term>Humains (MeSH)</term><term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term><term>Souris (MeSH)</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Proto-Oncogene Proteins c-akt</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines proto-oncogènes c-akt</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of growth regulatory signals originating from cell surface receptors.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS/CONCLUSIONS</b></p><p>The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18694380</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7631</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert opinion on therapeutic targets</Title><ISOAbbreviation>Expert Opin Ther Targets</ISOAbbreviation></Journal><ArticleTitle>Akt as a therapeutic target in cancer.</ArticleTitle><Pagination><MedlinePgn>1139-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14728222.12.9.1139 </ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of growth regulatory signals originating from cell surface receptors.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular.</AbstractText><AbstractText Label="RESULTS/CONCLUSIONS" NlmCategory="CONCLUSIONS">The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steelman</LastName><ForeName>Linda S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, Greenville, NC 27858, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadelman</LastName><ForeName>Kristin M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Chappell</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bäsecke</LastName><ForeName>Jörg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cervello</LastName><ForeName>Melchiorre</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Libra</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stivala</LastName><ForeName>Franca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Martelli</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>McCubrey</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01098195</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Targets</MedlineTA><NlmUniqueID>101127833</NlmUniqueID><ISSNLinking>1472-8222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>346</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18694380</ArticleId><ArticleId IdType="doi">10.1517/14728222.12.9.1139</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li></region></list><tree><noCountry><name sortKey="B Secke, Jorg" sort="B Secke, Jorg" uniqKey="B Secke J" first="Jörg" last="B Secke">Jörg B Secke</name><name sortKey="Cervello, Melchiorre" sort="Cervello, Melchiorre" uniqKey="Cervello M" first="Melchiorre" last="Cervello">Melchiorre Cervello</name><name sortKey="Chappell, William H" sort="Chappell, William H" uniqKey="Chappell W" first="William H" last="Chappell">William H. Chappell</name><name sortKey="Horn, Stefan" sort="Horn, Stefan" uniqKey="Horn S" first="Stefan" last="Horn">Stefan Horn</name><name sortKey="Libra, Massimo" sort="Libra, Massimo" uniqKey="Libra M" first="Massimo" last="Libra">Massimo Libra</name><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name><name sortKey="Nicoletti, Ferdinando" sort="Nicoletti, Ferdinando" uniqKey="Nicoletti F" first="Ferdinando" last="Nicoletti">Ferdinando Nicoletti</name><name sortKey="Stadelman, Kristin M" sort="Stadelman, Kristin M" uniqKey="Stadelman K" first="Kristin M" last="Stadelman">Kristin M. Stadelman</name><name sortKey="Stivala, Franca" sort="Stivala, Franca" uniqKey="Stivala F" first="Franca" last="Stivala">Franca Stivala</name></noCountry><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Steelman, Linda S" sort="Steelman, Linda S" uniqKey="Steelman L" first="Linda S" last="Steelman">Linda S. Steelman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001654 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001654 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18694380
|texte= Akt as a therapeutic target in cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18694380" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |